Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition

References

• Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19(4):237–13. doi:10.1038/s41571-021-00588-9.
   PubMed Web of Science ®Google Scholar
• Pires IS, Hammond PT, Irvine DJ. Engineering strategies for immunomodulatory cytokine therapies: challenges and clinical progress. Adv Ther. 2021;4(8):2100035. doi:10.1002/adtp.202100035.
   Google Scholar
• Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120(1):6–15. doi:10.1038/s41416-018-0328-y.
   PubMed Web of Science ®Google Scholar
• Amin A, White RL. Interleukin-2 in renal cell carcinoma: a has-been or a still-viable option? J Ren Cancer VHL. 2014;1(7):74–83. doi:10.15586/jkcvhl.2014.18.
   Google Scholar
• Zheng X, Wu Y, Bi J, Huang Y, Cheng Y, Li Y, Wu Y, Cao G, Tian Z. The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. Cell Mol Immunol. 2022;19(2):192–209. doi:10.1038/s41423-021-00786-6.
   PubMed Web of Science ®Google Scholar
• Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. OncoImmunology. 2017;6(3):e1277306. doi:10.1080/2162402X.2016.1277306.
   PubMed Web of Science ®Google Scholar
• Dolgin E. IL-2 upgrades show promise at ASCO. Nat Biotechnol. 2022;40(7):986–88. doi:10.1038/s41587-022-01390-3.
   PubMed Web of Science ®Google Scholar
• Jazayeri JA, Carroll GJ. Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs. 2008;22(1):11–26. doi:10.2165/00063030-200822010-00002.
   PubMed Web of Science ®Google Scholar
• Eliason JF. Pegylated cytokines: potential application in immunotherapy of cancer. BioDrugs. 2001;15(11):705–11. doi:10.2165/00063030-200115110-00001.
   PubMed Web of Science ®Google Scholar
• Murer P, Neri D. Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. N Biotechnol. 2019;52:42–53. doi:10.1016/j.nbt.2019.04.002.
   PubMed Web of Science ®Google Scholar
• Neri D, Sondel PM. Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol. 2016;40:96–102. doi:10.1016/j.coi.2016.03.006.
   PubMed Web of Science ®Google Scholar
• Saxton RA, Glassman CR, Garcia KC. Emerging principles of cytokine pharmacology and therapeutics. Nat Rev Drug Discov. 2023;22(1):21–37. doi:10.1038/s41573-022-00557-6.
   PubMed Web of Science ®Google Scholar
• Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong W-J, Sinha R, Guo F, Fabionar H, Wehrman TS, et al. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell. 2015;160(6):1196–208. doi:10.1016/j.cell.2015.02.011.
   PubMed Web of Science ®Google Scholar
• Harris KE, Lorentsen KJ, Malik-Chaudhry HK, Loughlin K, Basappa HM, Hartstein S, Ahmil G, Allen NS, Avanzino BC, Balasubramani A, et al. A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells. Sci Rep. 2021 [cited 2023 Feb 9];11(1): Available from https://www.nature.com/articles/s41598-021-90096-8
   Web of Science ®Google Scholar
• Yen M, Ren J, Liu Q, Glassman CR, Sheahan TP, Picton LK, Moreira FR, Rustagi A, Jude KM, Zhao X, et al. Facile discovery of surrogate cytokine agonists. Cell. 2022;185(8):1414–30.e19. doi:10.1016/j.cell.2022.02.025.
   PubMed Web of Science ®Google Scholar
• Yasuda K, Nakanishi K, Tsutsui H. Interleukin-18 in Health and Disease. Int J Mol Sci. 2019;20(3):649. doi:10.3390/ijms20030649.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 Binding Protein. Front Immunol [Internet]. 2013;4. [cited 2023 Feb 9]. http://journal.frontiersin.org/article/10.3389/fimmu.2013.00289/abstract.
   Web of Science ®Google Scholar
• Nakamura K, Bald T, Smyth MJ. Cancer‐killing, decoy‐resistant interleukin‐18. Immunol Cell Biol. 2020;98(6):434–36. doi:10.1111/imcb.12359.
   PubMed Web of Science ®Google Scholar
• Atallah-Yunes SA, Robertson MJ. Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives. Front Immunol [Internet]. 2022;13. [cited 2023 Feb 9]. https://www.frontiersin.org/articles/10.3389/fimmu.2022.872010/full.
   Web of Science ®Google Scholar
• Robertson MJ, Mier JW, Logan T, Atkins M, Koon H, Koch KM, Kathman S, Pandite LN, Oei C, Kirby LC, et al. Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer. Clin Cancer Res. 2006;12(14):4265–73. doi:10.1158/1078-0432.CCR-06-0121.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Millward M, Mainwaring P, Kefford R, Logan T, Pavlick A, Kathman SJ, Laubscher KH, Dar MM, Kirkwood JM. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer. 2009;115(4):859–68. doi:10.1002/cncr.24100.
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Kirkwood JM, Logan TF, Koch KM, Kathman S, Kirby LC, Bell WN, Thurmond LM, Weisenbach J, Dar MM. A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer. Clin Cancer Res. 2008;14(11):3462–69. doi:10.1158/1078-0432.CCR-07-4740.
   PubMed Web of Science ®Google Scholar
• Zhou T, Damsky W, Weizman O-E, McGeary MK, Hartmann KP, Rosen CE, Fischer S, Jackson R, Flavell RA, Wang J, et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature. 2020;583(7817):609–14. doi:10.1038/s41586-020-2422-6.
   PubMed Web of Science ®Google Scholar
• Roth L, Krah S, Klemm J, Günther R, Toleikis L, Busch M, Becker S, Zielonka S. Isolation of Antigen-Specific VHH Single-Domain Antibodies by Combining Animal Immunization with Yeast Surface Display. Methods Mol Biol. 2020;2070:173–89.
   PubMedGoogle Scholar
• Klausz K, Pekar L, Boje AS, Gehlert CL, Krohn S, Gupta T, Xiao Y, Krah S, Zaynagetdinov R, Lipinski B, et al. Multifunctional NK Cell–Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release. J Immunol. 2022;209(9):1724–35. doi:10.4049/jimmunol.2100970.
   PubMed Web of Science ®Google Scholar
• Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo K-M, Huston JS. Seedbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies†. Protein Eng Des Sel. 2010;23(4):195–202. doi:10.1093/protein/gzp094.
   PubMed Web of Science ®Google Scholar
• Pekar L, Busch M, Valldorf B, Hinz SC, Toleikis L, Krah S, Zielonka S. Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform. MAbs. 2020;12(1):1812210. doi:10.1080/19420862.2020.1812210.
   PubMed Web of Science ®Google Scholar
• de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, Horstman W, Engelberts PJ, Oostindie SC, Wang G, et al. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol. 2016;14(1):e1002344. doi:10.1371/journal.pbio.1002344.
   PubMed Web of Science ®Google Scholar
• Xue D, Hsu E, Fu Y-X, Peng H. Next-generation cytokines for cancer immunotherapy. Antib Ther. 2021;4(2):123–33. doi:10.1093/abt/tbab014.
   PubMedGoogle Scholar
• Holder PG, Lim SA, Huang CS, Sharma P, Dagdas YS, Bulutoglu B, Sockolosky JT. Engineering interferons and interleukins for cancer immunotherapy. Adv Drug Deliv Rev. 2022;182:114112. doi:10.1016/j.addr.2022.114112.
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Kline J, Struemper H, Koch KM, Bauman JW, Gardner OS, Murray SC, Germaschewski F, Weisenbach J, Jonak Z, et al. A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-hodgkin lymphoma. J Immunother. 2013;36(6):331–41. doi:10.1097/CJI.0b013e31829d7e2e.
   PubMed Web of Science ®Google Scholar
• Simpkins F, Flores A, Chu C, Berek JS, Lucci J, Murray S, Bauman J, Struemper H, Germaschewski F, Jonak Z, et al. Chemoimmunotherapy using pegylated liposomal doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase i dose-escalation study. Cancer Immunol Res. 2013;1(3):168–78. doi:10.1158/2326-6066.CIR-13-0098.
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Stamatkin CW, Pelloso D, Weisenbach J, Prasad NK, Safa AR. A dose-escalation study of recombinant human interleukin-18 in combination with ofatumumab after autologous peripheral blood stem cell transplantation for lymphoma. J Immunother. 2018;41(3):151–57. doi:10.1097/CJI.0000000000000220.
   PubMed Web of Science ®Google Scholar
• Novick D, Kim S-H, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 Binding Protein. Immunity. 1999;10(1):127–36. doi:10.1016/S1074-7613(00)80013-8.
   PubMed Web of Science ®Google Scholar
• Doerner A, Rhiel L, Zielonka S, Kolmar H. Therapeutic antibody engineering by high efficiency cell screening. FEBS Lett. 2014;588(2):278–87. doi:10.1016/j.febslet.2013.11.025.
   PubMed Web of Science ®Google Scholar
• Valldorf B, Hinz SC, Russo G, Pekar L, Mohr L, Klemm J, Doerner A, Krah S, Hust M, Zielonka S. Antibody display technologies: selecting the cream of the crop. Biol Chem. 2022;403(5–6):455–77. doi:10.1515/hsz-2020-0377.
   PubMed Web of Science ®Google Scholar
• Zielonka S, Empting M, Grzeschik J, Könning D, Barelle CJ, Kolmar H. Structural insights and biomedical potential of IgNAR scaffolds from sharks. MAbs. 2015;7(1):15–25. doi:10.4161/19420862.2015.989032.
   PubMed Web of Science ®Google Scholar
• Könning D, Zielonka S, Grzeschik J, Empting M, Valldorf B, Krah S, Schröter C, Sellmann C, Hock B, Kolmar H. Camelid and shark single domain antibodies: structural features and therapeutic potential. Curr Opin Struct Biol. 2017;45:10–16. doi:10.1016/j.sbi.2016.10.019.
   PubMed Web of Science ®Google Scholar
• Lipinski B, Arras P, Pekar L, Klewinghaus D, Boje AS, Krah S, Zimmermann J, Klausz K, Peipp M, Siegmund V, et al. Nkp46 ‐specific single domain antibodies enable facile engineering of various potent NK cell engager formats. Protein Science [Internet]. 2023 [cited 2023 Feb 17]; Available from;32(3): https://onlinelibrary.wiley.com/doi/10.1002/pro.4593
   Google Scholar
• Chanier T, Chames P. Nanobody engineering: toward next generation immunotherapies and immunoimaging of cancer. Antibodies. 2019;8(1):13. doi:10.3390/antib8010013.
   Web of Science ®Google Scholar
• Osbourn J, Groves M, Vaughan T. From rodent reagents to human therapeutics using antibody guided selection. Methods. 2005;36(1):61–68. doi:10.1016/j.ymeth.2005.01.006.
   PubMed Web of Science ®Google Scholar
• Teixeira AAR, Erasmus MF, D’Angelo S, Naranjo L, Ferrara F, Leal-Lopes C, Durrant O, Galmiche C, Morelli A, Scott-Tucker A, et al. Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries. MAbs [Internet]. 2021 [cited 2023 May 1];13(1): Available from https://www.tandfonline.com/doi/full/10.1080/19420862.2021.1980942
   Web of Science ®Google Scholar
• Rossotti MA, Bélanger K, Henry KA, Tanha J. Immunogenicity and humanization of single‐domain antibodies. FEBS J. 2022;289(14):4304–27. doi:10.1111/febs.15809.
   PubMed Web of Science ®Google Scholar
• Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem. 2009;284(5):3273–84. doi:10.1074/jbc.M806889200.
   PubMed Web of Science ®Google Scholar
• Sulea T. Humanization of camelid single-domain antibodies. In: Hussack G Henry K, editors. Single-Domain Antibodies. New York, NY: Springer US; 2022. pp. 299–312. [cited 2023 Mar 10]. InternetAvailable from: 10.1007/978-1-0716-2075-5_14.
   Google Scholar
• Duggan S. Caplacizumab: First Global Approval. Drugs. 2018;78:1639–42. doi:10.1007/s40265-018-0989-0.
   PubMed Web of Science ®Google Scholar
• SJ K. Ozoralizumab: First Approval. Drugs. 2023;83(1):87–92. doi:10.1007/s40265-022-01821-0.
   PubMed Web of Science ®Google Scholar
• Markham A. Envafolimab: First Approval. Drugs. 2022;82:235–40. doi:10.1007/s40265-022-01671-w.
   PubMed Web of Science ®Google Scholar
• van Kampen MD, Kuipers-De Wilt LHAM, van Egmond ML, Wilt LHAM K-D, van den Bremer ETJ, Wang G, Heck AJR, Parren P, Beurskens FJ, Schuurman J, et al. Biophysical characterization and stability of modified igg1 antibodies with different hexamerization propensities. J Pharmaceutical Sci. 2022;111(6):1587–98. doi:10.1016/j.xphs.2022.02.016.
   PubMed Web of Science ®Google Scholar
• Pekar L, Klausz K, Busch M, Valldorf B, Kolmar H, Wesch D, Oberg H-H, Krohn S, Boje AS, Gehlert CL, et al. Affinity Maturation of B7-H6 translates into enhanced NK cell–mediated tumor cell lysis and improved proinflammatory cytokine release of bispecific immunoligands via NKp30 Engagement. J Immunology. 2021;206(1):225–36. doi:10.4049/jimmunol.2001004.
   PubMed Web of Science ®Google Scholar
• Demaria O, Gauthier L, Vetizou M, Blanchard Alvarez A, Vagne C, Habif G, Batista L, Baron W, Belaïd N, Girard-Madoux M, et al. Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. Cell Rep Med. 2022;3(10):100783. doi:10.1016/j.xcrm.2022.100783.
   PubMedGoogle Scholar
• Benatuil L, Perez JM, Belk J, Hsieh C-M. An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng Des Sel. 2010;23(4):155–59. doi:10.1093/protein/gzq002.
   PubMed Web of Science ®Google Scholar
• Durocher Y. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 2002;30(2):9e–9. doi:10.1093/nar/30.2.e9.
   PubMed Web of Science ®Google Scholar
• Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Umaña P, Mössner E. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. 2016;29(10):457–66. doi:10.1093/protein/gzw040.
   PubMed Web of Science ®Google Scholar